BioTrove Inc. has filed for a $75 million IPO. The Woburn, Mass.-based company makes instruments and consumables for genomic analysis, high-throughput screening and molecular diagnostics. It plans to trade on the Nasdaq under ticker symbol BTRV, with Piper Jaffray and Lazard Capital Markets serving as co-lead underwriters.
BioTrove has raised over $43 million in VC funding since 2002, from firms like Catalyst Health & Technology Partners (35.1% pre-IPO stake), CB Health Ventures (17.1%), Vox Equity Partners (14.3%), Biofrontier Partners (6.1%), Fletcher Spaght Associates (6.2%) and Pfizer. www.biotrove.com